We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Heart Attack Test Delivers Results in One Hour

By LabMedica International staff writers
Posted on 27 Aug 2012
A more sensitive blood test for heart attack may cut the diagnosis time to one hour, removing the need for prolonged monitoring of patients who present to the Emergency Department (ED). More...


The test, which screens more sensitively for changes in a standard biochemical marker for myocardial infarction or heart attack, may help move patients more quickly through the ED, thus reducing congestion and saving time and money.

Scientists at the University Hospital Basel (Switzerland) recruited 872 patients who presented to the ED with acute chest pain in a multicenter study. The cornerstone for diagnosing acute myocardial infarction (AMI) relies on clinical assessment, electrocardiography and measurement of a biochemical marker called cardiac troponin (or cTn). Without a rapid test for the marker, it can take three hours or more to check for increases in levels.

Blood samples for the determination of high-sensitivity cardiac troponin (hs-cTnT) were collected in serum tubes at presentation to the ED and additional samples were collected hourly thereafter. The samples were assayed in a blinded fashion using the Elecsys 2010 analyzer (Roche Diagnostics; Basel Switzerland). The team developed an algorithm for half of the patients and validated it in the remaining half. The algorithm used baseline hs-cTnT and absolute changes in levels of the biochemical marker within the first hour.

The final diagnosis of AMI was made in 147 (17%) of the patients. When they validated the test in the second group of patients, within one hour it classed 60% (259 patients) of them as rule-out, 17% (76) as rule-in, and 23% (101) as being in the observational zone. They found the cumulative 30-day survival was nearly 100%, 98.6% and 95.3% for patients classed as rule-out, observational zone, and rule-in respectively.

Tobias Reichlin, MD, the lead author of the study said, "Using a simple algorithm incorporating hs-cTnT baseline values and absolute changes within the first hour allowed a safe rule-out as well as an accurate rule-in of AMI within one hour in 77% of unselected patients with acute chest pain. This novel strategy may obviate the need for prolonged monitoring and serial blood sampling in three of four patients." The study was published on August 13, 2012, in the journal Archives of Internal Medicine.

Related Links:

University Hospital Basel
Roche Diagnostics



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Following FDA clearance, providers can prescribe the kit, enabling labs to process home-collected urine specimens on cobas automated platforms (Photo courtesy of Orasure Technologies)

At-Home Urine Collection Kit Enables High-Throughput STI Screening

Sexually transmitted infection screening often hinges on access to private, convenient sample collection and timely laboratory processing. Many patients face logistical or privacy barriers that limit participation... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.